Skip to main content
. 2017 Feb 28;20:201–204. doi: 10.1016/j.rmcr.2017.02.011

Fig. 1.

Fig. 1

Clinical course of the patient. Top: Treatments and interventions. H, isoniazid; R, rifampicin; E, ethambutol; Z, pyrazinamide; L, levofloxacin; PSL, prednisolone; NAd, noradrenaline; NHF, nasal high flow; NIPPV, non-invasive positive pressure ventilation; IPPV, invasive positive pressure ventilation. Middle: Serum level of TNFα and whole-blood level of IFNγ. IFNγ-release assays were performed with the T-SPOT. TB and QuantiFERON TB Gold–In–Tube kits. T-SPOT panel A, the number of ESAT-6-specific spot-forming cells; T-SPOT panel B, the number of CFP-10-specific spot-forming cells. QFT TB, amount of IFNγ produced in response to TB antigen; QFT Mitogen, amount of IFNγ produced in response to stimulator; QFT Nil, non-specific baseline IFNγ level. Bottom: High-resolution computed tomography of the thorax on days 0, 25, and 37, showing progressive worsening of disseminated TB, followed by fibrosis.